ImmunityBio (IBRX) FY25 earnings call

ImmunityBio reported a transformational FY25, marked by significant commercial momentum for its lead asset, ANKTIVA, with substantial revenue and unit sales growth. The company achieved rapid international expansion, securing approvals in the EU and Saudi Arabia, while also progressing its pipeline across multiple platforms. Despite increased R&D investments, net loss narrowed, and the company is advancing its long-term strategy to diversify into a multi-platform oncology business, including AI-driven manufacturing.